Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. ARIMIDEX TABLET 1 MG [SIN09433P]

ARIMIDEX TABLET 1 MG [SIN09433P]

Active ingredients: ARIMIDEX TABLET 1 MG

Last updated 26 October 2025

On this page

Product Info
4.1 Therapeutic indications
4.2 Posology and method of administration
4.3 Contraindications

Product Info

ARIMIDEX TABLET 1 MG

[SIN09433P]

Product information

Active Ingredient and Strength

ANASTROZOLE - 1 MG

Dosage Form

TABLET, FILM COATED

Manufacturer and Country

ASTRAZENECA PHARMACEUTICALS LP - UNITED STATES

Registration Number

SIN09433P

Licence Holder

ASTRAZENECA SINGAPORE PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

L02BG03

4.1 Therapeutic indications

ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer.

Treatment of advanced breast cancer in postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer. Efficacy has not been demonstrated in oestrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen.

4.2 Posology and method of administration

Table caption

Adults including elderly

:

One 1mg tablet to be taken orally once a day

Children

:

Not recommended for use in children

Renal Impairment

:

No dose change is recommended in patients
with mild or moderate renal impairment

Hepatic Impairment

:

No dose change is recommended in patients
with mild hepatic disease.

For early disease, the recommended duration of treatment should be 5 years.

4.3 Contraindications

ARIMIDEX is contraindicated in:

  • premenopausal women.

  • pregnant or lactating women.

  • patients with severe renal impairment (creatinine clearance less than 20ml/min).

  • patients with moderate or severe hepatic disease.

  • patients with known hypersensitivity to anastrozole or to any of the excipients as referenced on the carton.

Oestrogen-containing therapies should not be co-administered with ARIMIDEX as they would negate its pharmacological action.

Concurrent tamoxifen therapy (see section 4.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).